Dawn of CAR-T cell therapy in autoimmune diseases
10.1097/CM9.0000000000003111
- VernacularTitle:Dawn of CAR-T cell therapy in autoimmune diseases
- Author:
Yuxin LIU
1
;
Minghao DONG
;
Yunhui CHU
;
Luoqi ZHOU
;
Yunfan YOU
;
Xiaowei PANG
;
Sheng YANG
;
Luyang ZHANG
;
Lian CHEN
;
Lifang ZHU
;
Jun XIAO
;
Wei WANG
;
Chuan QIN
;
Daishi TIAN
Author Information
1. Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
- Keywords:
CAR-T cell therapy;
Autoimmune disease;
Immunotherapy;
Multiple sclerosis;
Neuromyelitis optica spectrum disorder;
Systemic lupus erythematosus
- From:
Chinese Medical Journal
2024;137(10):1140-1150
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in the treatment of hematological malignancies. Based on the immunomodulatory capability of CAR-T cells, efforts have turned toward exploring their potential in treating autoimmune diseases. Bibliometric analysis of 210 records from 128 academic journals published by 372 institutions in 40 countries/regions indicates a growing number of publications on CAR-T therapy for autoimmune diseases, covering a range of subtypes such as systemic lupus erythematosus, multiple sclerosis, among others. CAR-T therapy holds promise in mitigating several shortcomings, including the indiscriminate suppression of the immune system by traditional immunosuppressants, and non-sustaining therapeutic levels of monoclonal antibodies due to inherent pharmacokinetic constraints. By persisting and proliferating in vivo, CAR-T cells can offer a tailored and precise therapeutics. This paper reviewed preclinical experiments and clinical trials involving CAR-T and CAR-related therapies in various autoimmune diseases, incorporating innovations well-studied in the field of hematological tumors, aiming to explore a safe and effective therapeutic option for relapsed/refractory autoimmune diseases.
